An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Psoriatic Arthritis
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Sponsors Novartis
- 29 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network, 9822).
- 29 Jun 2013 Planned patient number (42) added as reported by United Kingdom Clinical Research Network.
- 04 Mar 2013 New trial record